Back to top
more

XOMA (XOMA)

(Real Time Quote from BATS)

$25.12 USD

25.12
2,695

-0.24 (-0.95%)

Updated Apr 26, 2024 12:19 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow

by Zacks Equity Research

ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.

    FDA Okays J&J's Prostate Cancer Drug in First-Line Setting

    by Zacks Equity Research

    The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.

      Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

      by Zacks Equity Research

      Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

        Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4

        by Zacks Equity Research

        Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.

          Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

          by Zacks Equity Research

          Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

            Pfizer Files for Xtandi in Early Stage Prostate Cancer

            by Zacks Equity Research

            Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

              Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod

              by Zacks Equity Research

              The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.

                Puma, CANbridge Team Up to Commercialize Nerlynx in China

                by Zacks Equity Research

                Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.

                  Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review

                  by Zacks Equity Research

                  Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.

                    Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat

                    by Zacks Equity Research

                    Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.

                      Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label

                      by Zacks Equity Research

                      Amgen (AMGN) gains consent from the Committee for Medicinal Products for Human Use to add overall survival data from a phase III study on the label of its cancer drug, Kyprolis.

                        Puma & Medison Team Up to Commercialize Nerlynx in Israel

                        by Zacks Equity Research

                        Puma (PBYI) and Medison enters into a licensing deal to commercialize Puma's breast cancer treatment drug Nerlynx in Israel.

                          Debapriya Chakraborty headshot

                          Theravance's NDA for COPD Candidate Gets FDA Acceptance

                          by Debapriya Chakraborty

                          The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.

                            Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion

                            by Zacks Equity Research

                            The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.

                              Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y

                              by Zacks Equity Research

                              Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.

                                Shire Gets FDA Nod for Cinryze Tech Transfer to New Site

                                by Zacks Equity Research

                                Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.

                                  EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down

                                  by Zacks Equity Research

                                  Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.

                                    Anthera's Sollpura Strong on Positive Futility in Phase III

                                    by Zacks Equity Research

                                    Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.

                                      Regeneron's Dupixent Receives MHLW Nod for Label Expansion

                                      by Zacks Equity Research

                                      Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

                                        Bristol-Myers (BMY) Reports Data from CheckMate-142 Study

                                        by Zacks Equity Research

                                        Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab).

                                          Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%

                                          by Zacks Equity Research

                                          Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares nearly 9% on the day amid huge volumes.

                                            Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?

                                            by Zacks Equity Research

                                            Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.

                                              Arpita Dutt headshot

                                              3 Pharma and Biotech Stocks to Watch Out for in 2018

                                              by Arpita Dutt

                                              Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.

                                                Aradigm's Bronchiectasis Candidate Has Negative FDA Vote

                                                by Zacks Equity Research

                                                The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.

                                                  Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?

                                                  by Zacks Equity Research

                                                  We look at the factors that drive the share price of Perrigo to a 52-week high.